AdoraPet Biosciences

AdoraPet Biosciences

Early Stage

Invest in Pets that don't cause allergies

Invest in Pets that don't cause allergies

Overview

Raised this Round: Raised: $0

Total Commitments ($USD)

Platform

Dealmaker Securities

Start Date

12/18/2022

Close Date

04/10/2023

Min. Goal
$50,000
Max. Goal
$5,000,000
Min. Investment

$1,000

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$5.00

Pre-Money Valuation

$35,000,000

Year Founded

2022

Industry

Pet Health, Food, and Services

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Low

Capital Intensity

High

Location

San Mateo, California

Business Type

Growth

AdoraPet Biosciences, with a valuation of $20 million, is raising funds on DealMaker Securities. The company’s goal is to allow pets and owners to spend more time together by using state-of-the-art gene technology to eliminate the genes that cause allergies in owners and diseases in our pets. CRISPR is a Nobel Prize-winning technology scientists can use to remove problem-causing genes. AdoraPet plans to use CRISPR technology to modify these genes in embryos, creating allergy-free, long-living pets for everyone. Dr. Richard Chin, Dr. Stephen Sundlof and Dr. George Church founded AdoraPet in 2022. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5,000,000.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$0

$0

Summary Balance Sheet

FY 2022 FY 2021

Cash

$560

$0

Accounts Receivable

$0

$0

Total Assets

$560

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Financials as of: 12/18/2022
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
AdoraPet Biosciences on DealMaker 2022
Platform: Dealmaker Securities
Security Type: Equity - Common
Valuation: $35,000,000
Price per Share: $5.00

Follow company

Follow AdoraPet Biosciences on DealMaker 2022

Buy AdoraPet Biosciences's Deal Report

Warning: according to the close date for this deal, AdoraPet Biosciences may no longer be accepting investments.

AdoraPet Biosciences Deal Report

Get KingsCrowd’s comprehensive report on AdoraPet Biosciences including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether AdoraPet Biosciences is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the AdoraPet Biosciences deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge